They aren't questioning "negative" announcement of clinical trial result which IMU has never released, on the contrary they said the end of Ph2 clinical result for HER-Vaxx were excellent. There's still a market for HER-Vaxx as Chemotherapy will be the last option for cancer patient so why would patient want to use a drug which minimise the affect of using Chemo where in some instance it's actually the radiation which cause the death and not the cancer???
What they are questioning is the path for HER-Vaxx and PD1-Vaxx which are both at the most advanced development stage of all of IMU's IP. I think right now management is focusing on these 3 IP as they have FDA IND so BP will more than likely purchase the company once they are at similar development stage.
They aren't questioning "negative" announcement of clinical...
-
- There are more pages in this discussion • 614 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
-0.002(3.77%) |
Mkt cap ! $373.3M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.2¢ | 5.0¢ | $669.7K | 13.07M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1074997 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.2¢ | 1209633 | 6 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |